RCS - Cellbxhealth PLC - CelLBxHealth Presents Proof-of-Concept Study
05/11/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251105:nRSE1991Ga&default-theme=true
RNS Number : 1991G Cellbxhealth PLC 05 November 2025
5 November 2025
CELLBXHEALTH plc ("the Company")
CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics'
workflow at world-leading drug development conference
· Parsortix platform shown to be compatible with the Roche BenchMark
ULTRA automated staining system, with initial study of three key drug targets:
HER2 (breast), TROP2 (lung) and PSMA (prostate)
Guildford, UK and Plymouth Meeting PA, USA, - 5 November 2025 - CELLBXHEALTH
plc (AIM:CLBX OTCQX:ANPCY), a global leader in circulating tumour cell (CTC)
intelligence, announces the presentation of a proof-of-concept study using a
Roche Tissue Diagnostics workflow at the 16(th) World ADC conference, San
Diego, USA (Nov 3-6). The World ADC Conference is the largest global event
dedicated to antibody-drug conjugates (ADCs), attracting over 1,400 attendees
focused on advancing targeted cancer therapies.
Roche is a major diagnostics player, holding a significant share of the
overall tissue testing market. The Roche BenchMark ULTRA system is considered
a world leading clinical automated staining platform, with 95 patient samples
processed every minute, equating to more than 50 million samples a year(1).
The study showcases a novel workflow combining CelLBxHealth's Parsortix®
platform and proprietary CellKeep slide with Roche's BenchMark ULTRA automated
immunohistochemistry (IHC) staining platform for cell visualisation and
biomarker analysis across key ADC targets: HER2, TROP2, and PSMA.
Key findings from the collaboration include:
· Blood samples were successfully processed and cancer cell lines fixed
and shipped to Roche Tissue Diagnostics' site for automated IHC analysis using
Roche Tissue Diagnostics' HER2, TROP2 and PSMA assays
· For all biomarkers the BenchMark ULTRA automated IHC staining was
compatible with CelLBxHealth's manual immunofluorescent staining workflow
Characterisation of CTCs can overcome the limitations of tissue biopsies in
cancer care. A simple blood test offers a safer, faster, and less costly
alternative, enabling repeated testing when tissue isn't available. Since
cancer changes over time and with treatment, real-time monitoring is critical.
As living cells shed from the tumour into the blood, CTCs provide a dynamic
and up-to-date view of the patient's disease status.
The ADC market continues to grow rapidly, driven by the need for targeted,
effective treatments with fewer side effects. Integrating CTC-based biomarker
assessment into ADC development and clinical use could help optimise patient
selection and improve outcomes. CTCs are considered better biomarkers than
circulating tumour DNA (ctDNA) for selecting patients for ADC treatment
primarily because CTCs allow for the direct analysis of the target protein
expression on the cell surface, a critical requirement for ADC efficacy.
Peter Collins, Chief Executive Officer of CelLBxHealth, said: "We are pleased
to present initial results on our proof-of-concept study undertaken using
Roche Tissue Diagnostics' workflow. It is well known that targeted treatments
that utilise biomarkers improve patient outcomes. As such, this study
highlights the importance of targeted antigen expression on CTCs and their
relevance for potentially guiding ADC therapy selection in real-time.
CelLBxHealth believes these results highlight CTCs as accessible, dynamic
biomarkers in oncology. Leading experts believe that CTCs are poised to add
clinical utility to the metastatic landscape(2)."
For more information, visit www.cellbxhealth.com.
References:
1.
www.diagnostics.roche.com/us/en/products/instruments/discovery-ultra-ins-2210.html
2. Nicolò, E., et al. (2025). International expert consensus on the clinical
integration of circulating tumor cells in solid tumors. European Journal of
Cancer, 231, 116050. https://doi.org/10.1016/j.ejca.2025.116050
For further information:
CelLBxHealth plc +44 (0) 1483 343434
Peter Collins, Chief Executive Officer investors@CelLBxHealth.com
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper (Corporate Finance) +44 (0) 20 7220 0500
Sunila de Silva (Corporate Broking)
Nigel Birks (Life Science Specialist Sales)
FTI Consulting
Simon Conway, Ciara Martin, Sam Purewal +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a global precision CTC intelligence company specialising
in innovative circulating tumour cell (CTC) solutions for use in research,
drug development and clinical oncology. Its patent-protected Parsortix®
platform harvests CTCs from blood and can be seamlessly integrated with
existing laboratory instruments for comprehensive downstream analysis -
including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities centre on (1) Product Sales: Accelerating Parsortix
platform adoption and consumable sales through CROs* and clinical lab
partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme (3) Laboratory services:
Clinical trial support and assay development.
The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP certified UK laboratory, providing bespoke clinical-trial support and
assay development.
For more information, visit www.CelLBxHealth.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUSVARVBUARUA
Copyright 2019 Regulatory News Service, all rights reserved